{"brief_title": "Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-020)(COMPLETED)", "brief_summary": "The purpose of this study is to determine the safety and efficacy of an investigational drug in patients with type 2 diabetes mellitus.", "condition": ["Diabetes Mellitus, Type II"], "intervention_type": ["Drug", "Drug", "Drug", "Drug"], "intervention_name": ["Sitagliptin (MK0431)", "Placebo/Glipizide 5 mg", "Metformin", "Pioglitazone"], "description": ["Sitagliptin 100 mg once daily, from Visit 4 through Final Visit, week 104", "Placebo (to match Sitagliptin 100 mg) from Visit 4 through Visit 8; Glipizide 5 mg from Visit 8, week 24 to Final Visit (Week 104)", "Metformin 1500 mg, once daily, from Visit 2 to Final Visit (Week 104)", "Pioglitazone 15 mg once daily, for patients not meeting specific glycemic goals during the placebo-controlled treatment period [Phase A], from Visit 5 (Week 6) to Visit 8 (Week 24)"], "arm_group_label": ["Sitagliptin 100 mg", "Placebo / Glipizide 5 mg", "Sitagliptin 100 mg", "Placebo / Glipizide 5 mg", "Sitagliptin 100 mg", "Placebo / Glipizide 5 mg"], "other_name": ["MK0431", "sitagliptin phosphate", "Januvia", "ACTOS"], "criteria": "Inclusion Criteria: - Patients with type 2 diabetes mellitus", "gender": "All", "minimum_age": "18 Years", "maximum_age": "78 Years", "healthy_volunteers": "No", "keyword": "Type 2 Diabetes Mellitus", "mesh_term": ["Diabetes Mellitus", "Diabetes Mellitus, Type 2", "Pioglitazone", "Metformin", "Sitagliptin Phosphate", "Glipizide"], "id": "NCT00086515"}